Substance / Medication

Eliglustat tartrate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Profile of eliglustat tartrate in the management of Gaucher disease.
Sechi Annalisa, Dardis Andrea, Bembi Bruno · Ther Clin Risk Manag · 2016
PMID: 26811686ReviewFull text (PMC)
Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease.
Bennett Lunawati L, Turcotte Kelsey · Drug Des Devel Ther · 2015
PMID: 26345314ReviewFull text (PMC)
Eliglustat tartrate, a prototypic glucosylceramide synthase inhibitor.
Shayman James A · Expert Rev Endocrinol Metab · 2013
PMID: 30736134Other
Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers.
Peterschmitt M Judith, Burke Amy, Blankstein Larry et al. · J Clin Pharmacol · 2011
PMID: 20864621Trial
A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.
Lukina Elena, Watman Nora, Arreguin Elsa Avila et al. · Blood · 2010
PMID: 20439622TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Eliglustat tartrate (substance)
SNOMED CT
863995003
UMLS CUI
C3272699

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.